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Abstract
Background: The study investigated the feasibility of conducting a future Randomised Controlled Trial (RCT) of a
mobile health (mHealth) intervention for weight loss and HbA1c reduction in Type 2 Diabetes Mellitus (T2DM).
Methods: The intervention was a small wearable mHealth device used over 12 weeks by overweight people with
T2DM with the intent to lose weight and reduce their HbA1c level. A 4 week maintenance period using the device
followed. The device records physical activity level and information about food consumption, and provides motivational
feedback based on energy balance. Twenty-seven participants were randomised to receive no intervention; intervention
alone; or intervention plus weekly motivational support. All participants received advice on diet and exercise at the start
of the study. Weight and HbA1c levels were recorded at baseline and weeks 6, 12, and 16. Qualitative interviews were
conducted with participants who received the intervention to explore their experiences of using the device and
involvement in the study including the training received.
Results: Overall the device was perceived to be well-liked, acceptable, motivational and easy to use by participants.
Some logistical changes were required during the feasibility study, including shortening of the study duration and
relaxation of participant inclusion criteria. Descriptive statistics of weight and HbA1c data showed promising trends of
weight loss and HbA1c reduction in both intervention groups, although this should be interpreted with caution.
Conclusions: A number of methodological recommendations for a future RCT emerged from the current feasibility
study. The mHealth device was acceptable and promising for helping individuals with T2DM to reduce their HbA1c and
lose weight. Devices with similar features should be tested further in larger studies which follow these methodological
recommendations.
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Background
Overview
Obesity is the leading risk factor for Type 2 Diabetes
Mellitus (T2DM) [1]. Around 62 % of the population in
England and Wales are overweight or obese [2], and in the
United Kingdom (UK) the overall prevalence of diabetes is
around 4.5 % (with around 90 % of these expected to have
T2DM) [1, 3]. The costs to the National Health Service
(NHS) are significant, with around £10 billion per year
spent on diabetes [1]. High prevalence and costs of T2DM
are reflected on a global scale [4].
Weight loss is an important goal in the treatment of
overweight and obese T2DM patients [5]. Intentional
weight loss in T2DM can lead to reduced clinical symp-
toms, reduced use of medications, and reduced mortality
risk [6]. National guidelines for T2DM treatment
emphasise the integration of optimal dietary advice and
increased physical activity within a multi-component
diabetes management plan [3]. This multi-component
approach can help individuals with T2DM to achieve
HbA1c, blood pressure and lipid profiles in or near to
the normal range [3].
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Recently the use of mobile health (mHealth, e.g. apps on
mobile phones, pedometers) for self-management of
T2DM has received attention as a potentially cost-effective
strategy for weight reduction and improved glycaemic con-
trol [7–11]. A recent systematic review [12] concluded that
mHealth-based interventions can lead to short-term (and
potentially medium-term) clinically significant weight loss
for some overweight and obese adults. Portable technology
enables interventions to be employed by individuals whilst
going about their daily lives [13], and facilitates self-
monitoring, which is acknowledged as a key component of
weight loss intervention programmes. In addition
interactive technology can be designed to assist people in
modifying their attitudes and behaviours [14]. However,
Randomised Controlled Trials (RCTs) which aim to assess
the effectiveness of mHealth for weight loss typically have
significant methodological weaknesses including a lack of
blinding, and often, too little information on randomisa-
tion, measures to address attrition, and delivery of partici-
pant education [12].
Study context
The current study aimed to initiate the process of evaluat-
ing a specific mHealth intervention, in order to develop
more robust evidence on whether this intervention could
be used to help people with T2DM lose weight and
control their HbA1c levels.
The aforementioned systematic review [12] identified a
promising CE (European Conformity) marked mobile
digital technology for overweight/obese T2DM patients,
the AiperMotion 440 [15]. Its primary impact on a user
is assumed to be adding greater motivation overtly and
through empowerment to self-monitor. A 2011 study
(based in Germany) reported that after 6 months of
using the device the intervention group of overweight/
obese T2DM patients had a greater mean weight loss
and greater reduction in HbA1c compared to the control
group [15]. In addition, diabetic medication was discon-
tinued or reduced in 81 % of intervention participants
(compared to 0 % in the control group). These promising
results require verification because of: the researchers’
close working with the device manufacturers; unknown
details about the participants and operational details of
the trial; potential exaggeration because of the small num-
ber of participants (n = 68); personal financial cost to par-
ticipants for taking part; and a lack of UK-based data
(which was deemed important by clinical advisors to the
current project). The value of the authors’ study is that it
will inform an RCT that doesn’t have these shortcomings.
Following the 2011 study the device was superseded
by the AiperMotion 500, which was smaller and lighter,
had a longer battery life and a colour screen, provided
anthropomorphic-visual motivational feedback and
allowed the user to make retrospective ‘corrections’ to
calorie and physical activity data. In accordance with the
Medical Research Council’s (MRC) Complex Interven-
tion guidelines [16] we planned a feasibility study to
determine the acceptability of the AiperMotion 500 and
the feasibility of conducting an RCT of the intervention
in the UK, as a first step to more robust evaluation of
the effectiveness of the intervention. The manufacturers
were aware of the project but were not involved.
Methods
Research aims and objectives
The primary aim of the study was to investigate the feasi-
bility of conducting a future mixed-methods RCT of an
mHealth supported weight loss intervention (AiperMotion
500) for overweight/obese individuals with T2DM. The
primary objectives were to include measures to address
the above noted shortcomings of other studies, review
operation of the study (especially including recruitment,
randomisation procedures, and attrition) and explore
participants’:
 Views of the education on diet, exercise and use of
the technology;
 Views on acceptability of the technology;
 Adherence to using the technology;
 Perception of how motivational the technology was;
 Experience of taking part in the study.
The measurement of weight loss and change in HbA1c
and inflating participant numbers allowed a secondary
aim of obtaining an initial indication of any weight loss
and HbA1c trends. Thus the secondary objective was to:
 Compare mean weight loss and HbA1c change
across the study arms using descriptive statistics.
Design
The mixed methods feasibility study occurred during
April–December 2013 (the maximum time available
from funding), 5 weeks setting up the study ending in
launching public awareness of the study, 5 weeks for re-
cruitment (incorporating the training sessions), 20 weeks
for participation and, 9 weeks for analyses and write up.
For the feasibility study each participant was asked to
take part for 12 weeks aiming at weight loss and blood
sugar reduction followed by 8 weeks of maintenance of
their achievement (reflecting the goal of achieving and
observing a longer term change in behaviour and
maintained weight loss/blood sugar reduction [17]).
These durations were judged sufficient for the primary
objectives and minimally sufficient for the secondary ob-
jectives. Longer durations for both goals of reduction
and maintenance in any future trial were anticipated but
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were beyond resource and duration limits of the feasibility
study.
Participants were randomly allocated to one of three
groups:
 Group One-advice on diet and exercise;
 Group Two-as Group One plus use of
AiperMotion 500;
 Group Three-as Group Two plus email motivational
support (to echo other AiperMotion studies [15]).
For the purposes of the primary study objectives meth-
odologically recruiting around ten participants in total
could be seen as sufficient, but for the secondary aim
and objective more would be needed. About ten par-
ticipants in each arm was judged as minimally suffi-
cient, but to account for high published attrition rates
(47–60 %) [18, 19] twenty in each arm was selected
as a suitable ambition.
Intervention
The AiperMotion 500 is a wearable device, preferably
worn at the hip (with less accuracy it can be carried in a
pocket or bag). Added motivation to lose weight occurs
through user awareness of the device’s automatic record-
ing of physical activity, the act of recording nutritional
intake for eating healthily, and receiving graphical and
pictorial feedback on these measures (both immediately
and over time). The features of the device are outlined
in Fig. 1.
For Group 3 further motivational impact may have
occured through emailed sending of weekly event diaries
and receiving motivational feedback in return.
Procedures
At the beginning of the 12 week intervention all partici-
pants received 90-min group training, delivered by the
research team, around appropriate behaviours to lose
weight and control their HbA1c, specifically:
 Eating a low Glycaemic Index (GI) diet (this
included the first hand experiences, tips on
cheap information sources and ingredients, and
tasting of example baked foods with low GI);
 Maximising physical activity;
 Neuro-Linguistic Programming (NLP) was also
employed as the primary motivational component of
the training to enable participants to visualise
themselves at their ideal weight and then set goals
to reach it. NLP relies on making an individual
aware of their subconscious sensations, movements,
language and perceptions (as well as their conscious
ones), and using this to explore alternative ways of
thinking about their hopes, behaviours and
experiences [20].
All participants were given a booklet summarising the
training. While participants were encouraged to try the
low-GI diet they were told they could choose to follow
their preferred diet if it had been previously successful.
The recommendation regardless of the selected diet was
Fig. 1 Features of AiperMotion 500
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to combine this with increased physical activity. Partici-
pants were also told they could individually choose their
own weight-loss goal to increase motivation.
Randomly arranged pre-sealed envelopes were used to
randomly allocate individual participants to study
groups; the envelopes were held by a responsible person
who was physically remote from the training and inde-
pendent from the study. At the end of training one of
the researchers contacted the responsible person, who
opened the next envelope and over the telephone re-
vealed the next participant’s allocation. Allocation was
concealed from participants and researchers until train-
ing was completed.
Groups Two and Three then received a further 60 min
training in use of the AiperMotion 500 during which
their individual characteristics (weight, height, gender
and age) were entered into their devices. These partici-
pants were asked to wear the device during waking
hours and to report the amount of time that they en-
gaged in physical activity where the device was not worn
(e.g. swimming). They were also asked to enter dietary
information into the device whenever they consumed
food or drink (apart from water). They could choose to
enter exact calorific values or category of meal and por-
tion size. The motivational feedback was also highlighted
to them. Participants in Group Three were asked to send
weekly emails to the research team describing any posi-
tive or negative events which had impacted their con-
formance with the study or motivation to lose weight,
and any behaviour changes, during the previous week
(‘Event Diaries’). Emailed replies delivered tailored posi-
tive encouragement—thus potentially adding further
positive motivation. If an Event Diary was not received
then a reminder was sent to the participant.
Table 1 provides an overview across the three arms
and individual participant’s entire timelines of their ex-
posure to training, study measures and data collection.
Each participant’s five visits should accumulate to about
280 min. As can be seen this involved a combination of
quantitative and qualitative measures to address the
research aims including those of the anticipated fu-
ture trial.
As can be seen in Table 2 the 12 week intervention
was followed by a weight maintenance period. Originally
intended to be 8 weeks in length, due to slower and
lower recruitment than aimed for, the investigators
reduced this to just 4 weeks (so that 4 further weeks
could be spent recruiting more participants to address
the secondary objective within the available duration).
Group 3 Event Diaries and associated motivational
emails were stopped during the maintenance period; but
all participants were asked to continue using their
device. Table 2 summarises the participants’ intended
activities over the 16 weeks.
Use of the device
It is useful to also describe the expected use of the de-
vice the participants would make during the study. The
device starts a new record for each calendar day at mid-
night. Participants would start by putting the device
onto their clothing (ideally at the hip, but otherwise else-
where, but if really necessary putting it into a bag they
carry). The device immediately starts to record their
physical activity automatically. If they wish they can alter
their physical activity goals for that day. Similarly the
goal daily calorific reduction can be set, or change in
weight recorded. All of these values would be anticipated
to be changed only occasionally—e.g. when the user
wants to reset their goals.
After each occasion they have eaten or drunk some-
thing they make a calorific entry into the device—choos-
ing whether they will use the quick estimated choices of
type and size of meal, or to calculate the exact calorific
value and enter that. The former choices are calibrated
to the user’s BMI, so nominally entering an appropriate
number of ‘normal’ sized selections would lead to no
weight change, ‘small’ and ‘large’ leading to weight loss
and gain respectively.
Table 1 Participant activities at research venue visits
In week Actions/Events Group
1
Group
2
Group
3
1 Answer baseline questionnaire ✓ ✓ ✓
Collection of blood samples for
HbA1c
✓ ✓ ✓
Measure height and weight ✓ ✓ ✓
Training on diet and weight loss ✓ ✓ ✓
Randomisation ✓ ✓ ✓
Training on use of the device – ✓ ✓
Training on email support – – ✓
6 Measure weight ✓ ✓ ✓
Collection of blood samples
for HbA1c
✓ ✓ ✓
Download data from device – ✓ ✓
12 Measure weight ✓ ✓ ✓
Collection of blood samples
for HbA1c
✓ ✓ ✓
Answer repeat questionnaire ✓ ✓ ✓
Download device data – ✓ ✓
Interviews/focus groups – ✓ ✓
16 Measure weight ✓ ✓ ✓
Collection of blood samples
for HbA1c
✓ ✓ ✓
Answer repeat questionnaire ✓ ✓ ✓
Download device data – ✓ ✓
Interviews/focus groups – ✓ ✓
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If they need to remove the device from their clothing
at any time then they can add a calorific value to the ex-
ercise record. The device allows them to select a type of
physical activity and its duration—making an estimate of
the energy burnt based on their BMI.
At any time they can obtain motivational feedback that
is based on food intake, energy burnt and their BMI. On
the screen they can see an anthropomorphic figure and
get a sense of how they are doing that day, or they can
choose to view the results and examine the calorific
values of exercise and food and the energy balance, or
look at how much of the required time for their exercise
goals they have achieved, for that day or for up to the
preceeding 7 days. More graphical visualisation of the
device-collected data can be viewed by them download-
ing the data to software on their computers where
longer periods of time can be reviewed.
Outcome measures
Quantitative
Participants completed a questionnaire at baseline, at
the end of the intervention, and at the end of mainten-
ance. The questionnaire [see Additional file 1] recorded:
 Demographic information including : at baseline age,
gender, height, education, employment status, use of
ICT; on all occasions living circumstances, medical
history, medications, willingness to change,
notification of any change in circumstance;
 Health behaviours, on all occasions, such as dietary
habits, physical activity, smoking behaviour, and
alcohol intake.
Participants visited the NIHR Clinical Research Facility
(CRF) at the Royal Hallamshire Hospital in Sheffield at
weeks 0, 6, 12 and 16. During these visits weight (kg)
was measured using a SECA medical class III body
weight scale, and height was checked at baseline using a
wall-mounted stadiometer. A blood sample was taken at
each visit to assess HbA1c. Device data on dietary
intake, physical activity and data entry time logs were
downloaded at week 6, 12 and 16. The research team
maintained trial management records in which levels of
participation and attrition (including any volunteered
reasons for withdrawal) were logged.
Qualitative
Qualitative focus groups and (where participants pre-
ferred it) individual interviews were conducted with a
convenience sample of participants from Group Two
and Three to explore perceptions of the technology’s
acceptability and motivational value, and experiences of
being involved in the study. The Technology Acceptance
Model (TAM) for Mobile Services [21] informed devel-
opment of the interview guide on issues relating to the
device; inspiring questions/topics for discussion based
around the: value to users, ease of use, trust (including
perceived reliability), and ease of adoption. To add to
this participants were asked for their views on the
education/training session at the start of the study and
were invited to share comments/views on any other
relevant topic. Interviews and focus groups were audio-
recorded and transcribed verbatim.
Participants
Overweight and obese members of the public in South
Yorkshire with T2DM were recruited through advertis-
ing via the volunteer database for The University of
Sheffield, Facebook, posters in public places, local news-
papers and third sector organisations. Interest was indi-
cated by telephone or email after viewing the study’s
website (which included the participant information
sheet). They were then invited to attend a one on one
introductory session at which written informed consent
was collected and a training date booked. Participants
were offered £10 cash per visit as nominal reimburse-
ment (which was not declared in the advertisements).
The eligibility criteria for the study were as follows:
Inclusion criteria:
 Diagnosed with T2DM;
Table 2 Participant aims and planned use of interventions
during their participation
Timeframe Participant aims and
interventions
Group 1 Group 2 Group 3
Weeks 1–12 Aim to reduce HbA1c and
weight
✓ ✓ ✓
Follow their choice of diet ✓ ✓ ✓
Follow their choice of
exercise
✓ ✓ ✓
Measure their weight
regularly
✓ ✓ ✓
Adhere to use of device
if available
– ✓ ✓
Send & receive emails
weekly
– – ✓
Week 13–16 Aim to maintain HbA1c
and weight
✓ ✓ ✓
Adapt their diet as
necessary
✓ ✓ ✓
Adapt their exercise as
necessary
✓ ✓ ✓
Measure their weight
regularly
– ✓ ✓
Adhere to use of device
if available
– ✓ ✓
Send & receive emails
weekly
– – –
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 Aged 30–60 years;
 Body Mass Index (BMI) between 25 and 40;
 Aiming to lose 5 % or more of body weight through
managing diet and exercise;
 Willing to use Information Technology (IT);
 Able to communicate and read in English
(limitation of the technology).
Exclusion criteria:
 Pregnant, planning to become pregnant, or had been
pregnant within 6 months of the study starting;
 Taking medication which affects weight, e.g.
antidepressants;
 Diagnosed with a chronic condition other than
T2DM, including mental health conditions;
 Used computer software, a website or mobile
app within the last 6 months to reduce weight
or blood sugar;
 Unwilling to use IT;
 Cognitive or other significant impairments which
impede ability to participate or give informed
consent.
The inclusion and exclusion criteria were similar to
those used in Luley’s RCT with AiperMotion 440
[15], with the exception that pregnancy was a reason
for exclusion but vegetarianism was not, and although
T2DM diagnosis was a requirement, heightened
HbA1c or regular use of antidiabetic medication was
not. Furthermore, participants in the current study
were permitted to use any weight loss approach pro-
vided they were not delivered using mHealth or other
remote communication technology, echoing the RCT
from Haapala [22]. Clinical experience and evidence
[23] suggested the 30–60 age range as potentially
more receptive than older ages to the use of digital
technology to influence health. The goal was 60 re-
cruits (20 per arm) which exceeds that usually
employed to observe any major issues regarding the
feasibility of a methodology and/or an intervention,
but offers the potential for initial insight of the clin-
ical changes due to the intervention and pre-empts
possible high attrition rates seen in previous studies
on obesity (47–60 %) [18, 19].
Data analysis and statistics
Frequency of wearing the device (i.e. to monitor physical
activity) and frequency of entering dietary information
were used to provide an indication of participants’
adherence to use of the device. Qualitative data were
categorised into a priori and emerging themes in accord-
ance with Framework Analysis [24]. Descriptive statistics
were used to summarise weight and HbA1c changes
across the groups and timeframes.
Results
Results are presented following the order of the Primary
and Secondary research objectives.
Primary research objectives
Recruitment to the study
As there was a requirement for participants to have IT
literacy, visits to the study website provide an indication
of public awareness and interest in the study. The web-
site in a 2 month period (when visit data were available)
had 210 unique visits and 524 page views. 38 % of
visitors viewed pages beyond the home page. Table 3
summarises the visits to individual pages, omitting the
home and index pages and any not visited at all.
While researchers reported that at least 85 people
enquired about the study, the logs of telephone enquiries
indicate 65 attempts to be recruited. Table 4 summarises
the recorded reasons that were identified to exclude
participation.
The recruitment rate was slower than anticipated.
Recruitment was extended by 4 weeks (and correspond-
ingly the maintenance period was shortened to 4 from
8 weeks). The study was advertised in May, June and
July while recruitment occurred during June and July.
To increase recruitment, inclusion criteria were also
relaxed to include Type 1 Diabetes and ages up to 65,
resulting in seven extra recruits.
Twenty-seven participants were recruited to the study
(nine to each Group). These participants became aware
of the study as follows: fifteen via emailed invitations to
consider participation; three from third party online
promotion of the study; two via newspaper adverts; two
from posters displayed in public venues; and five via
word of mouth.
A summary of participants’ demographic characteristics
at Baseline is shown in Table 5. Although participants
diagnosed with depression or receiving prescribed anti-
depressant medication were excluded from the study, two
made it into the study as they had not revealed this
information when recruited.
Table 3 Study website statistics over 2 months
Web page No. of visits
Eligibility 47
The Study 46
Volunteering 45
Study Details 35
Volunteering Details 33
Detailed Eligibility 33
Contact 22
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Randomisation
Randomisation took place in the group setting at the
end of training. One participant became distressed
upon finding out that they had been allocated to the
control group, exacerbated by being told within the
training group setting, which in turn also hampered
the research team’s ability to support the participant.
This issue was subsequently managed by segregating
participants into study arm groups before they were
told their allocation.
Although the allocated Groups were comparable on
most demographics, there were significant differences
across gender and socio-economic status indicators.
For example, there were no males and more partici-
pants renting accommodation in the control group,
and a greater proportion of professionally employed
participants in Group 3. However these baseline
demographic differences between groups can be at-
tributed to the small sample size.
No other problems were encountered with
randomisation.
Attrition and loss to follow up
During the 16 week study out of the 108 (i.e. 27 × 4)
total planned participant visits to the research venue 94
were achieved. By the end of the study five participants
were lost due to attrition, two more were lost to follow
up, together this amounts to 26 % of the sample. Of
these, five withdrew prior to the end of the 12 week
intervention period (Group 1: 2; Group 2: 1; Group 3:
2), and a further 2 participants were lost to follow up
from Group 3 in the weeks 12 and 16 period. The exit
questionnaire [see Additional file 2] was sent to those
withdrawing, and ill health or moving out of the area
were volunteered as reasons for withdrawal. However
one also mentioned too frequent visits and parking being
a problem at the research venue. No one mentioned
problems or issues with use of the Aipermon 500 device
or with the training.
Qualitative analysis results
Group Two and Three participants took part (6 males, 3
females) in qualitative interviews and focus groups.
Qualitative data were coded into the following naturally
emergent themes (unsurprisingly some of which corre-
lated with those from the TAM for Mobile Services):
 Diet, exercise and device training (cf education)
 Ease of adoption (cf acceptability)
 Trustworthiness (cf acceptability)
 Ease of use (cf adherence)
 Value (cf perception of motivation)
The above list highlights the match to the primary
research objectives shown in brackets. The following
results sub-sections report illustrative and specific
results relating to training, acceptability, adherence, and
perception of motivational value (as shown above). Any
significant additional information available from the
Table 4 Reasons for exclusion of the 38 enquirers not recruited
to the study
Reason for exclusion No. of enquirers
Not diabetic 6
Too old or too young (respectively) 6 + 1
BMI too high or too small (respectively) 7 + 1
Unwilling or unable to use IT 2
Taking weight—affecting medication 2
Other serious medical condition 2
Cannot attend the required visits to research facility 4
No reasons recorded/failed to establish dialogue 14
Table 5 Demographics of Study Participants at Baselinea
Characteristic Group 1
(n = 9)
Group 2
(n = 9)
Group 3
(n = 9)
Total
(N = 27)
Age in years, Mean (SD) 55.7(9.9) 52.1(7.8) 50.8(8.1) 52.9(8.6)
Male 0(0) 5(55.6) 7(77.8) 12(44.4)
Female 9(100) 4(44.4) 2(22.2) 15(55.6)
Ethnicity
British 7(77.8) 8(88.9) 8(88.9) 23(85.2)
Irish 1(11.1) 0(0) 0(0) 1(3.7)
Asian 0(0) 1(11.1) 0(0) 1(3.7)
African 1(11.1) 0(0) 0(0) 1(3.7)
Caribbean 0(0) 0(0) 1(11.1) 1(3.7)
Living Circumstances
Living with others 7(77.8) 8(88.9) 6(66.7) 21(77.8)
Living alone 2(22.2) 1(11.1) 3(33.3) 6(22.2)
Socio-Economic Status
Professional employmentb 3(33.3) 2(22.2) 7(77.8) 11(40.7)
Home owned outright 4(44.4) 2(22.2) 3(33.3) 8(29.6)
Mortgage 1(11.1) 5(55.6) 5(55.6) 12(44.4)
Rented 4(44.4) 1(11.1) 1(11.1) 6(22.2)
Physical Activity & Diet History
Physical Activity: Never/Rarely 4(44.4) 4(44.4) 3(33.3) 11(40.7)
: Sometimes 3(33.3) 4(44.4) 5(55.6) 12(44.4)
: Often 2(22.2) 1(11.1) 1(11.1) 4(14.8)
Tried dieting in the past 9(100) 5(55.6) 7(77.8) 21(77.8)
Weight loss success 8(88.9) 6(66.7) 7(77.8) 21(77.8)
aData are represented as the number (percentage) of study participants unless
stated otherwise
bImplying level of education and current and/or past as in
socio-economic profiling
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execution of the study is also reported. The final primary
research objective of experience of taking part in the
study is reported at the end.
Diet, exercise and device training
The education/training sessions around diet and exercise,
and use of the device, generated mainly positive com-
ments but with a few negatives, e.g. :
“I found it very good ….. I was left in no doubt as to
the importance of the diet …. and the types of food you
should be avoiding”. P1/018
“I was confident yes (to use the device after training) … I
went in (the device) and went home and put all the
data in and then put it on the following day”. P1/023
“Confident to use the device after training?, No”. P1/020
The exercise training, while mentioned in the intro-
duction in the focus groups, was not a specific sub-
topic—although there was an open opportunity to
comment. There were no comments specifically about
the exercise training, positive or negative, but there
were comments indicating doing more exercise (most
often with reference to motivation attributed to the
device):
“I constantly use the stairs so yes it has made it different.
I think about walking instead of riding”. P1/023
‘I’m just far more active’. P1/009
Receiving a booklet with the training information in
it, the signposting to low-GI diet guides, and practical
knowledge of one of the trainers in making low-cost
low-GI selections and baking, were appreciated. Two
participants had minor problems with device training
and required extra practice during the training
session.
A few individuals disliked the NLP element of the
training. It asked participants to visualise themselves at
their ideal weight, a task which some participants found
upsetting as they felt the exercise and its implied weight
loss were unrealistic.
Acceptability
Three participants did seek (and were given) help in in-
stances where they wanted to correct for errors they had
made when entering exact calorific values. The focus
groups mainly suggested that the device was easy to in-
corporate into their everyday lives, although problems
were reported:
“Certain clothes that I wore it was difficult to keep
on…a skirt or more dressy trousers it would dig in…
that’s nothing compared to the benefits”. P1/009
In another case a participant adapted how they carried
the device even though it was not in the preferred loca-
tion for accuracy:
“I usually keep it in my bag…I don’t think anybody
thinks (anything) about it you know, it is just there”.
P1/005
Opinions were mixed, too, on how trustworthy the
data in the device were:
“Whatever you put into it is accurate…but it’s whether
your (calorie) counting is accurate”. P1/012
“What it said on the machines (at the gym) was not
necessarily what was registering (on the device)”. P1/012
There were 3 instances of data being lost due to faulty
or lost devices—creating some gaps in the data
collected.
Adherence (to using the technology)
The focus group participants reported the device was
easy to use, in some cases linking it directly to adhering
to increased exercise or dieting :
“It is quite a simple straightforward device and the
size is not that intrusive… I found it extremely easy
(to enter information)… I found it fine, no problem at
all”. P1/008
“I’ve used it so to me that shows my interest is high,
otherwise it would be sitting on the side and it would
be unused”. P1/009
“I think it’s made me really positive, I really do watch
what I’m doing and I do get cross if I put it on and I’ve
not done loads of steps (laughs)”. P1/023
There were also some comments implying summer
holidays may have interfered with adhering to use of the
device and in following their chosen diet and physical
exercise programme.
An objective and quantitative perspective on adherence
is added through considering the days the device was
worn and days on which diet was entered. Adherence has
been simply calculated as: the number of days the device
had been worn divided by the total number of days partic-
ipants had the opportunity to wear the device; and, the
number of days on which at least 950 cal of nutritional
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information were inputted divided by the total number of
days participants had the opportunity to input nutritional
information. The threshold of 950 cal was adopted as
representing a minimal level of nutritional intake on a
given day.
Table 6 shows the levels of adherence to the use of the
device in this study. These adherence averages are calcu-
lated including ‘missing data’ when participants were un-
able to provide the daily monitoring data (due to their
devices being lost or broken/faulty). Across the 16 weeks
four participants in Group 2 and another four in Group
3 wore their devices for in excess of 90 % of available
days; the days recording their diet for the participants in
these sub-groups averaged to 87 and 81 % respectively.
Based on the above definition there was generally greater
adherence to wearing the device than to inputting nutri-
tional information.
Group 3 participants were also asked to submit weekly
emails from which they would receive motivational feed-
back. Adherence to this over the 12 weeks it operated
was low at an average of 31 % (3 participants supplied
7–9 emails, 2 supplied 3 or 4, and the remaining 4
supplied 0 or 1). Those who supplied 0 or 1 emails
correlated exactly with those who withdrew or were lost
to follow up in Group 3.
Perception of motivational value
In addition to the quotations from P1/009 to P1/023 in
the preceding Adherence section there were further in-
dications of positive motivational value of the device:
“Getting the cup, the motivation it gives you that’s the
biggest plus of it all, it motivates you in a way that
nothing else does because it’s constantly measuring
what you’re doing”. P1/009
“Having the device does make you think and do things
differently…my sugars have been the best they’ve ever
been”. P1/026
But some reported disadvantages or negative experiences
(e.g. in comparison with a face-to-face intervention):
“It has not really (changed my behaviour), I’ve been a
bit stressed and moody…it is to do with other things”.
P1/005
“I might have been better with a trainer or a coach”.
P1/026
There were also mixed comments about the weekly
email dialogues :
“keeps you going”. P1/001
“I found it amusing to get these support emails ….. if
people take an interest in you and your results then
that can modify one’s behaviour” P1/020
“I haven’t religiously sent the emails …. If I didn’t have
anything positive to say I didn’t really want to send
the email (laughs)”. P1/018
Experiences of involvement in the study
Participants reported that they felt that the study staff
were always on hand and very helpful. Attendance at the
research facility at agreed dates and times was not per-
fect. There were several occasions where agreed visits
had to be re-arranged—usually because of a failure to
arrive rather than a planned re-arrangement. Partici-
pants in most cases of both planned and unplanned re-
arrangements gave reasons based on being too busy or
another commitment.
With the range of BMI of recruited participants there
were a couple of those with higher BMI who felt uncom-
fortable with the presence of people at the lower end of
the study BMI range. The latter were mainly people with
Type 1 diabetes.
As the study was not funded or approved to take
advantage of the technically possible uploading of data
to a third party secure online server a more manual
process had to be adopted. Participants had to hand over
their devices during research facility visits. The data
would then be downloaded by the researchers, which
proved cumbersome. However, some participants had a
worse experience because they had completely down-
loaded the data from their devices to their computers at
home. This made the process much more difficult for
the affected participants as they had to be given instruc-
tions for copying the required folders and files to a
memory stick to bring to the visits to the research facil-
ity. With occasional delays requiring extra support this
was still completed successfully with the exception of
those participants lost to follow up.
Focus group participants were generally satisfied with
their experience of being involved in the study, and
many stating that they enjoyed using the intervention
and were satisfied with the technology. A few expressed
Table 6 Adherence to using the Device by Participants with
collected Weight measurements
Weeks Group 2 Group 3
n % worna % diet entriesb n % worna % diet entriesb
1–6 9 62 62 8 61 58
7–12 8 65 59 7 69 70
13–16 8 75 49 5 94 70
aPercentage of days worn from total days of access to the device
bPercentage of days of nutritional data of at least 950 cal was entered from
total days access to the device
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difficulties with keeping to their chosen diet or dissatis-
faction with having to calculate calories to then enter
into the device. Some of these reported converting to
using the device preset meal types and sizes instead and
ended up being satisfied like those who had chosen to
use this method early on—all participants using this
method found it easy and acceptable. A majority
expressed a willingness to take part in future studies if
possible.
Secondary research objectives
Weight and HbA1c
Tables 7 and 8 shows that participants in Groups 2 and 3
(with the device) had greater reductions in weight and
HbA1c compared to Group 1 (without the device). Infer-
ential analyses were not conducted as the sample sizes
were small, thus this trend should be interpreted with
caution.
Discussion
This study was the first attempt to independently evalu-
ate the acceptability and potential effectiveness of the
AiperMotion 500 in a UK setting. Overall the device was
well-liked and perceived to be acceptable, motivational
and easy to use by most participants. Good average
levels of adherence with wearing the device and input-
ting nutritional data were observed (NB faulty or lost
devices created gaps in the device data which in turn
reduced the averages reported in Table 6), supporting
previous studies which show that providing ‘real-time’
feedback in self-monitoring is valued [25]. However, a
certain amount of polarity in adherence of individuals to
using the device was evident. With more detailed obser-
vation any polarity in use of mHealth to monitor phys-
ical and dietary activity by individual participants might
be investigated in future pre-trial studies. Although cau-
tion should be employed in interpreting the quantitative
results of the study, the mHealth intervention does show
promise in helping people with T2DM to reduce their
weight and HbA1c levels. The email motivational feed-
back, while possibly causing higher adherence to use of
the device, did not appear to make a difference to the
amount of weight loss and HbA1c reduction observed,
although again caution should be employed.
Increased motivation attributable to the use of the de-
vice is of course an important factor in considering the
results presented here. In reality the added motivation
occurs within a context—including many influences e.g.
the participants’ routine environment, life events, and
experiences from other elements of the study. There was
no intent to separate or directly observe the motivation
from the device. Beyond participants’ comments the
study evidence can only give inferences about motiv-
ational impact indirectly from the results on adherence,
acceptability, attrition, and from the weight and HbA1c
changes. These results also broadly imply a useful and
positive motivational impact.
Recent systematic reviews demonstrate the potential
of portable technology for weight reduction in adults
[26–28]. However there is an acknowledged lack of
rigorous RCT evidence in this area [26, 27], as well as
uncertainty around the effectiveness of mHealth com-
pared to other weight loss interventions [26], whether
any benefits are sustained long-term [27, 28], which
components of mHealth are most effective [29], which
populations should be targeted [26], and whether they
would be technically and financially viable for use on a
larger scale [27]. The current feasibility study is an
important first step towards answering some of these
questions for weight loss in the T2DM population, and
will be used to inform the design of a future RCT.
Problems were discovered with some of the practical-
ities of conducting the study, including recruitment and
randomisation, inclusion/exclusion criteria, length of
maintenance period and nature of the education session.
An attrition rate and loss to follow up of 26 % is still a
concern and rather than one significant cause there
seems to have been a number of contributory factors for
the participants in this study, including traumatic
events/illness in the family, busy lives, frequency/density
of visits to the research facility, and difficulties with
parking at the research facility. Due to time and budget-
ary constraints, only 27 of the target 60 participants
were recruited; even after attrition and loss to follow up
those remaining were still sufficient to inform the feasi-
bility of operating a future RCT.
The results demonstrated that it is feasible to conduct
an RCT investigating the effectiveness of an mHealth de-
vice in aiding weight and HbA1c reduction in T2DM
(with a view to conducting a large multi-site RCT), as-
suming that modifications to the methodology are made:
1. The inclusion and exclusion criteria should be less
prescriptive so that people over the age of 60, people
with co-morbid depression, and people with other
co-morbid long term conditions, are included. Some
older T2DM patients will be interested in using
technology to manage their condition [30] and open
to use of digital technology [23]. There is a high rate
of co-morbid depression [31] and other co-morbid
long term conditions [32] among people with
T2DM. It might be argued, despite some individuals
on anti-depressant medications experiencing weight
gain [33], that they could still benefit. Including such
participants may require special allowances in the
protocol.
2. The study duration should be substantially increased
to include longer periods of weight/HbA1c
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Table 7 Summary of Means, Ranges, and Changes from Baseline in Weight
Group 1 Group 2 Group 3
Baseline Wk 6 Wk 12 Wk 16 Baseline Wk 6 Wk 12 Wk 16 Baseline Wk 6 Wk 12 Wk 16
(n = 9) (n = 8) (n = 7) (n = 7) (n = 9) (n = 9) (n = 8) (n = 8) (n = 9) (n = 8) (n = 7) (n = 5)
Weight (kg)
Mean 98.6 100.0 101.2 101.1 95.8 93.1 89.5 89.1 102.0 97.8 99.1 95.1
Range 83.0–110.8 83.0–111.4 83.4–111.8 84.0–110.4 74.2–123.0 73.0–121.0 73.5–108.2 73.6–108.6 91.2–113.4 87.2–108.2 85.2–110.4 84.2–103.6
Mean change from Baseline – +0.1 +0.8 +0.7 – −2.7 −2.9 −3.3 – −3.0 −3.2 −3.0
Range change from Baseline – −1.0 to +1.6 −0.2 to + 2.1 −0.6 to +2.0 – −5.0 to–1.2 −7.4 to–0.7 −8.8 to–0.6 – −8.6 to +0.4 −12.0 to +2.0 −13.0 to +3.0
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Table 8 Summary of Means, Ranges, and Changes from Baseline in HbA1c
Baseline Wk 6 Wk 12 Wk 16 Baseline Wk 6 Wk 12 Wk 16 Baseline Wk 6 Wk 12 Wk 16
(n = 9) (n = 7) (n = 6a) (n = 7) (n = 9) (n = 8) (n = 8) (n = 6a) (n = 9) (n = 8) (n = 6a) (n = 3a)
HbA1c (mmol/mol)
Mean 60.4 60.9 64.3 63.6 57.6 54.0 50.6 49.2 65.8 58.6 57.7 46.3
Range 44.0–106.0 44.0–106.0 40.0–107.0 43.0–101.0 44.0–78.0 42.0–81.0 36.0–66.0 38.0–63.0 48.0–115.0 45.0–115.0 41.0–79.0 43.0–53.0
Mean change from Baseline – −0.9 0.0 +0.9 – −4.8 −8.1 −10.7 – −2.9 −14.8 −5.0
Range change from Baseline – –9.0 to +5.0 –4.0 to +3.0 –5.0 to +9.0 – –12 to +3.0 –13.0 to 0.0 –26.0 to 0.0 – –10.0 to 0.0 –39.0 to–2.0 –12.0 to +2.0
aEither one or two participants’ results being missing due to sample handling errors (not withdrawal)
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reduction and maintenance, in order to determine
the long term effects of using this intervention.
Twelve weeks was short for the ultimate weight loss
goals of many of the participants. Although not
explored at the time of the study, such a device as
the Aipermon 500 (i.e. the intervention used here)
would be well suited for a user to aim for an energy
balance of zero during weight maintenance.
3. The randomisation process should take place in
private rather than in a group setting. Support
should be in place if participants become distressed
by their allocation, and ideally all participants should
be offered the opportunity to use the device after
the study has completed (although this would
increase the cost of an RCT).
4. Any additional motivational techniques to encourage
adherence should be of known value in weight loss
and/or diabetes; where any uncertainty exists
(perhaps as with NLP) they should be evaluated
separately.
5. Participants should be recruited through diabetes
clinics and other healthcare sources, rather than
through public advertisements alone, in order to
access the T2DM population pool more directly. It
may be useful to note that after the study an NHS
formed public involvement group reviewed the
recruitment materials (to inform what should be
used for the future RCT). Their view was that the
information on the study website pages was entirely
sufficient and that the ethically required detailed
Participant information sheets were unnecessary,
if not off putting.
6. In light of the slow recruitment and failure to reach
the target sample size the previous modifications on
their own may not be enough. Thus some further
measures to improve recruitment should be
considered, e.g. a longer period to recruit. Financial
incentive is another. Simply advertising and paying
participants to take part, even if linked to just
making sure they adhere to the administrative basics
of the study, may increase recruitment without
undue impact on outcomes. Financial motivation
tied to individual participant success during a
study has been shown to be effective as an
intervention in its own right; however in the
longer term follow up of the benefit is also
reported to be eroded [34].
7. Careful consideration should be given to the
location of any visits participants make for the study.
For instance, use of a health service facility as a
location to collect blood samples seems appropriate
but if at all possible there should be easy parking at
and travel to the location. Use of local clinics, GP
surgeries or other places where the participant’s
journey is shortened and made easy may help to
reduce attrition.
8. People are not homogeneous in their confidence or
capability to use ICT. Despite having reported ease
of use, having on request responsive individualised
support to using any technology during the early
weeks of the study (i.e. period of adoption of the
device) may help both with adherence and reduce
attrition. As a minimum offering video instructions
for participants to access at home (rather than just
printed material) should be considered.
9. Including explicit opportunities for participants to
report faulty or lost devices may not only improve
data collection but, similarly to the previous
modification, also improve adherence and
reduce attrition.
10. More blinding measures should be included, for
instance so that any staff taking physiological
readings are not aware of a participant’s
allocation [12].
11. Approval should be sought to allow the automatic
transfer of data from the device to a secure server
which can be seen and downloaded by the research
team and the healthcare professional(s) responsible
for the individual’s care. This would mean fewer
visits to the CRF, resulting in less chance of
attrition, loss to follow-up and loss of data, and
greater convenience for participants.
12. Adherence in this study was calculated based on
overall percentages for wearing the device and
inputting of nutritional values. Use of simple
convenient estimates of adherence is not untypical
for similar published studies. However this neither
considers the voracity of the collected data nor the
true complexity of adherence to behaviour change
interventions [35]. In a future RCT it may be more
appropriate to consider adherence as a ‘specific’
measure to individual patients [35] before
considering ways to judge adherence across a trial.
A pilot RCT, followed by a full scale RCT, with suitably
amended protocols are required to evaluate the promising
trends identified in the feasibility study and to provide a
robust indication of effectiveness. Unfortunately, since the
feasibility study’s completion, the AiperMotion 500 has
been withdrawn as its manufacturer stated it wished to in-
vest its resources in other health product lines. Uncer-
tainty around willingness of individuals or health services
to purchase the technology, especially with burgeoning
competition from smart phone fitness apps, may have
contributed to this decision. At the time of the study the
AiperMotion 500 was unique from many other mHealth
interventions due to the combination of its characteristics:
CE marking as a medical product, anthropomorphic
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pictorial feedback; flexibility to allow the user to enter
either estimated or specific calorific values for food
consumed; allowing input of additional exercise when the
device was not worn; and in allowing secure cloud or
server-based sharing of individual patient data with
healthcare professionals. Features of the AiperMotion 500
were highly valued and therefore ideally an app or device
incorporating similar features needs to be found or devel-
oped in order to continue evaluation of this intervention.
However it is noted that a meta-analysis of digital inter-
ventions for T2DM suggests feature variation between in-
terventions has only minor effects on blood glucose
results [36], so there is room for some variation in features
in a future version of the intervention.
Conclusions
The feasibility study has been a valuable first step to-
wards informing evaluation of the effectiveness of an
mHealth-based complex intervention for weight loss/
HbA1c reduction in T2DM, in accordance with the
MRC framework [16]. Methodological lessons will be
carried forward into an RCT of a similar intervention
but may also more generally be considered in similar
feasibility studies of other mHealth technologies for
obesity and/or diabetes. An intervention based on tech-
nology with similar features to the AiperMotion 500 is a
potentially acceptable and promising aid for individuals
with T2DM to control their HbA1c and weight.
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